Non-alcoholic fatty liver disease: A patient guideline

被引：192

作者：

Francque, Sven M. ^{[1
,2
,3
,4
]}

Marchesini, Giulio ^{[5
,6
]}

Kautz, Achim ^{[7
]}

Walmsley, Martine ^{[8
]}

Dorner, Rebecca ^{[7
]}

Lazarus, Jeffrey, V ^{[9
]}

Zelber-Sagi, Shira ^{[10
,11
]}

Hallsworth, Kate ^{[12
,13
]}

Busetto, Luca ^{[14
,17
]}

Fruhbeck, Gema ^{[15
,17
]}

Dicker, Dror ^{[16
,17
]}

Woodward, Euan ^{[17
]}

Korenjak, Marko ^{[18
]}

Willemse, Jose ^{[19
]}

Koek, Gerardus H. ^{[20
,21
]}

Vinker, Shlomo ^{[22
,23
,24
,25
,26
]}

Ungan, Mehmet ^{[23
]}

Mendive, Juan M. ^{[27
,28
]}

Lionis, Christos ^{[28
,29
]}

机构：

[1] Antwerp Univ Hosp, Dept Gastroenterol & Hepatol, Antwerp, Belgium

[2] Univ Antwerp, Fac Med & Hlth Sci, Lab Expt Med & Paediat LEMP, Antwerp, Belgium

[3] Univ Antwerp, InflaMed Ctr Excellence, Antwerp, Belgium

[4] Univ Antwerp, Translat Sci Inflammat & Immunol, Antwerp, Belgium

[5] Univ Bologna, IRCCS Azienda Osped, Bologna, Italy

[6] Alma Mater Univ, Dept Med & Surg Sci, Bologna, Italy

[7] Kautz5 gUG, Cologne, Germany

[8] PSC Support, Oxford, England

[9] Univ Barcelona, Hosp Clin, Barcelona Inst Global Hlth ISGlobal, Barcelona, Spain

[10] Univ Haifa, Fac Social Welf & Hlth Sci, Sch Publ Hlth, Haifa, Israel

[11] Tel Aviv Med Ctr & Sch Med, Dept Gastroenterol & Hepatol, Tel Aviv, Israel

[12] Newcastle Upon Tyne Hosp NHS Fdn Trust, Newcastle NIHR Biomed Res Ctr, Newcastle Upon Tyne, Tyne & Wear, England

[13] Newcastle Univ, Fac Med Sci, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England

[14] Univ Padua, Dept Med, Padua, Italy

[15] Univ Navarra Clin, Dept Endocrinol & Nutr, CIBEROBN, IdiSNA, Pamplona, Spain

[16] Rabin Med Ctr Hasharon Hosp, Dept Internal Med, Tikva, Israel

[17] European Assoc Study Obes, Teddington, Middx, England

[18] European Liver Patients Assoc, Brussels, Belgium

[19] Liver Patients Int, Maastricht, Netherlands

[20] Maastricht Univ, Div Gastroenterol & Hepatol, Dept Internal Med, Med Ctr, Maastricht, Netherlands

[21] Maastricht Univ, Sch Nutr & Translat Res Metab NUTRIM, Maastricht, Netherlands

[22] Tel Aviv Univ, Sackler Fac Med, Dept Family Med, Tel Aviv, Israel

[23] World Org Family Doctors WONCA, Geneva, Switzerland

[24] European Gen Practice Res Network EGPRN, Leipzig, Germany

[25] Israel Assoc Family Phys, Tel Aviv, Israel

[26] Leumit Hlth Serv, Tel Aviv, Israel

[27] Catalan Inst Hlth, Training Unit Family Med, Barcelona, Spain

[28] European Soc Primary Care Gastroenterol, Ljubljana, Slovenia

[29] Univ Crete, Sch Med, Clin Social & Family Med, Iraklion, Greece

来源：

JHEP REPORTS | 2021年 / 3卷 / 05期

关键词：

LIFE-STYLE MODIFICATION; SERUM ALANINE AMINOTRANSFERASE; PLACEBO-CONTROLLED TRIAL; Y GASTRIC BYPASS; QUALITY-OF-LIFE; BARIATRIC SURGERY; PHYSICAL-ACTIVITY; HEPATOCELLULAR-CARCINOMA; HEPATIC STEATOSIS; UNITED-STATES;

D O I：

10.1016/j.jhepr.2021.100322

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and comes with a high disease burden. Yet, there is a lot of unawareness. Furthermore, many aspects of the disease are still to be unravelled, which has an important impact on the information that is given (or not) to patients. Its management requires a close interaction between patients and their many healthcare providers. It is important for patients to develop a full understanding of NAFLD in order to enable them to take an active role in their disease management. This guide summarises the current knowledge relevant to NAFLD and its management. It has been developed by patients, patient representatives, clinicians and scientists and is based on current scientific recommendations, intended to support patients in making informed decisions. (C) 2021 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).

引用

页数：39

共 285 条

[1] Risks of Light and Moderate Alcohol Use in Fatty Liver Disease: Follow-Up of Population Cohorts [J].

Aberg, Fredrik ;

Puukka, Pauli ;

Salomaa, Veikko ;

Mannisto, Satu ;

Lundqvist, Annamari ;

Valsta, Liisa ;

Perola, Markus ;

Farkkila, Martti ;

Jula, Antti .

HEPATOLOGY, 2020, 71 (03) :835-848

[2] Binge drinking and the risk of liver events: A population-based cohort study [J].

Aberg, Fredrik ;

Helenius-Hietala, Jaana ;

Puukka, Pauli ;

Jula, Antti .

LIVER INTERNATIONAL, 2017, 37 (09) :1373-1381

[3]

Abner Erin L, 2011, Curr Aging Sci, V4, P158

[4] Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases [J].

Adams, Leon A. ;

Anstee, Quentin M. ;

Tilg, Herbert ;

Targher, Giovanni .

GUT, 2017, 66 (06) :1138-1153

[5] Outcomes of Bariatric Surgery in Patients with Liver Cirrhosis: a Systematic Review [J].

Ahmed, Saleem ;

Pouwels, Sjaak ;

Parmar, Chetan ;

Kassir, Radwan ;

de Luca, Maurizio ;

Graham, Yitka ;

Mahawar, Kamal .

OBESITY SURGERY, 2021, 31 (05) :2255-2267

[6] Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis [J].

Aithal, Guruprasad P. ;

Thomas, James A. ;

Kaye, Philip V. ;

Lawson, Adam ;

Ryder, Stephen D. ;

Spendlove, Ian ;

Austin, Andrew S. ;

Freeman, Jan G. ;

Morgan, Linda ;

Weeber, Jonathan .

GASTROENTEROLOGY, 2008, 135 (04) :1176-1184

[7]

Ajmera V, 2018, CLIN GASTROENTEROL H, V16, P341, DOI [10.1016/j.cgh.2017.11.040, 10.1016/j.cgh.2018.01.026]

[8] The metabolic syndrome - a new worldwide definition [J].

Alberti, KGMM ;

Zimmet, P ;

Shaw, J .

LANCET, 2005, 366 (9491) :1059-1062

[9]

Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO

[10]

2-S

← 1 2 3 4 5 6 7 8 9 10 →